Monsanto Company

Pharmacia Corporation

G.d. Searle & Company

G.d. Searle LLC

Genentech, Inc.

Feder, Joseph

Harakas, Nicholaos K.

Connolly, Daniel T.

Wittwer, Arthur J.

Schaumann, Jon P.

Joseph Feder

Jitka V. Olander

Daniel T. Connolly

Daniel T Connolly

James A Sikorski

Kevin C Glenn

Daniel L Flynn

Len F Lee

Jeffery A Zablocki

Bradley T Keller

Shridhar G Hegde

Ashton T Hamme, Ii

Michele A Melton

Roger J Schilling

David G Corley

Nancy N Wall

Mark E Smith

Steven P Adams

Arthur J Wittwer

Joseph R Schuh

Jitka V Olander

Jon P Schaumann

Nicholaos K Harakas

Pamela J Keck

Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity

The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an ileal bile acid transport inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications

A cDNA having a base sequence for human vascular permeability factor has been cloned and characterized and the amino acid sequence of the human vascular permeability factor protein has been determined.

DNA sequences encoding human vascular permeability factor having 189

Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.

Large scale production of plasminogen activator from normal human colon

A method of producing antibodies against vascular permeability factor (VPF) is disclosed which comprises immunizing a host animal with a peptide having an amino acid sequence as follows: ##STR1## or a fragment of said peptide containing an antigenic determinant of VPF.

Antibodies to VPF

A method of stimulating endothelial cell growth is provided which comprises subjecting said cells to a growth stimulating amount of a highly purified vascular permeability factor having the following characteristics:

Stimulation of endothelial cell growth

A method is disclosed for determining the number of cells in cell culture which comprises lysing the cells and incubating the cell lysate with p-nitrophenyl phosphate for a predetermined period of time at acid pH and at 35.degree.-38.degree. C., and then measuring the color development at 400 to 420 nanometers and comparing with a control. The method is accurate, sensitive, and well-suited for automation, and thereby provides for the rapid sampling of large numbers of cell culture where the cells are grown under very sparse conditions.

Method of determining the number of cells in cell culture

Growing community of inventors

Manchester, MO, United States of America

Daniel T Connolly